Abstract
Background The association between transthyretin cardiac amyloidosis (TTR-CA) and aortic stenosis (AS) has been described, although the mechanism by which they interact remains unclear. It has previously been proposed that this may be secondary to excess valvular calcification.
Objectives We propose that patients with suspected cardiac amyloidosis will have increased aortic valve calcification, as evidenced by elevated aortic valve calcium score on CT imaging.
Methods We retrospectively identified patients with severe AS referred for transcatheter aortic valve implantation (TAVI) from January 2017 to November 2022. This population was divided into two cohorts; the Likely CA cohort had suspected TTR-CA by echocardiogram while the Unlikely CA cohort did not. Baseline characteristics, echocardiographic data, CT aortic valve calcium scores, and post-procedural complications were compared.
Results Of the 496 patients analyzed, 145 (29.2%) patients met echocardiographic criteria (interventricular septal thickness (IVS) ≥1.2 cm and average mitral annular systolic s’ ≤ 6 cm/s) for the Likely CA cohort. The Likely CA cohort was more likely to be older, be male, have atrial fibrillation, and have worse renal function. On echocardiogram, the Likely CA cohort had increased hypertrophy, worsened diastolic function, and decreased systolic function. Aortic valve calcium score by CT was not significantly different between the Likely CA and Unlikely CA cohort (2834.95 AU compared to 2852.27 AU, p=0.914). There was no statistically significant difference in post-TAVI complications.
Conclusions Patients with an echocardiographic profile consistent with TTR-CA had no difference in aortic valve calcification in comparison to a population unlikely to have TTR-CA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding support was acquired for this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The design of this study was approved by the Scripps Health Institutional Review Board and Ethics Committee and performed in accordance with institutional guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Daniel Ng Jr: None.
Karine Moussa: None.
Francis W Allinson: None.
Adam Behroozian: None.
Timothy M Jordan: None.
Leah Puglisi: None.
Curtiss T Stinis: Edwards Lifesciences, consultant and speaker. Paul S Teirstein: None.
RCM: AstraZeneca, consultant. Pfizer, consultant.
Funding: None.
Data Availability
The data was obtained from the STS/ACC TVT of Scripps patients as approved by the Scripps IRB.
